Novel Radiological Brain Anomalies in a Patient with Congenital Muscular Dystrophy due to FKRP Mexican Founder Mutation c.1387A > G: Review of the Literature

Abstract

Mutations in the FKRP gene result in phenotypes with severe forms of congenital muscular dystrophies (CMD) and limb-girdle muscular dystrophies. We present a Mexican patient with a pathogenic homozygous mutation in the FKRP gene (c.1387A > G, p.Asn463Asp) and CMD with radiological brain anomalies as disseminated hyperintensity lesions and discrete generalized cortical atrophy. These findings have not been reported to the best of our knowledge in other patients with the same mutation. The mutation c.1387A > G, p.Asn463Asp in the FKRP gene has been described to have a founder effect in central Mexico, since all the patients described to date are of Hispanic origin. Therefore, we emphasize studying mutations in the FKRP gene in Hispanic pediatric patients with clinical suspicion of CMD. Clinical and molecular diagnosis of specific CMD subtypes is needed to help clarify the prognosis, management, and genetic counseling to the patient and families.

Keywords

FKRP gene - congenital muscular dystrophy - founder mutation

Note

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standard.

Publication History

Received: 12 December 2020

Accepted: 08 February 2021

Article published online:
14 April 2021

• References

• 1 Sparks SE, Escolar DM. Congenital muscular dystrophies. Handb Clin Neurol 2011; 101: 47-79
• 2 Quijano S, Gómez M. Distrofias musculares congénitas. Rev Med Clin Las Condes 2018; 29 (05) 530-543
• 3 Cataldi MP, Blaeser A, Lu P, Leroy V, Lu QL. ISPD overexpression enhances Ribitol-induced glycosylation of α-dystroglycan in dystrophic FKRP mutant mice. Mol Ther Methods Clin Dev 2019; 17: 271-280
• 4 Gumlaw N, Sevigny LM, Zhao H. et al. biAb mediated restoration of the linkage between dystroglycan and laminin-211 as a therapeutic approach for α-dystroglycanopathies. Mol Ther 2020; 28 (02) 664-676
• 5 Lee AJ, Jones KA, Butterfield RJ. et al. Clinical, genetic, and pathologic characterization of FKRP Mexican founder mutation c.1387A>G. Neurol Genet 2019; 5 (02) e315
• 6 Gonzalez-Perez P, Smith C, Sebetka WL, Gedlinske A, Perlman S, Mathews KD. Clinical and electrophysiological evaluation of myasthenic features in an alpha-dystroglycanopathy cohort (FKRP-predominant). Neuromuscul Disord 2020; 30 (03) 213-218
• 7 Cohn RD. Dystroglycan: important player in skeletal muscle and beyond. Neuromuscul Disord 2005; 15 (03) 207-217
• 8 Esapa CT, McIlhinney RA, Blake DJ. Fukutin-related protein mutations that cause congenital muscular dystrophy result in ER-retention of the mutant protein in cultured cells. Hum Mol Genet 2005; 14 (02) 295-305
• 9 Fu X-N, Xiong H. Genetic and clinical advances of congenital muscular dystrophy. Chin Med J (Engl) 2017; 130 (21) 2624-2631
• 10 Kim J, Lana B, Torelli S. et al. A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan. EMBO Rep 2019; 20 (11) e47967
• 11 Brockington M, Blake DJ, Prandini P. et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 2001; 69 (06) 1198-1209
• 12 MacLeod H, Pytel P, Wollmann R. et al. A novel FKRP mutation in congenital muscular dystrophy disrupts the dystrophin glycoprotein complex. Neuromuscul Disord 2007; 17 (04) 285-289
• 13 Navarro-Cobos MJ, González-Del Angel A, Estandia-Ortega B. et al. Molecular analysis confirms that FKRP related disorders are underdiagnosed in Mexican patients with neuromuscular diseases. Neuropediatrics 2017; 48 (06) 442-450
• 14 Angelini C, Pinzan E. Advances in imaging of brain abnormalities in neuromuscular disease. Ther Adv Neurol Disorder 2019; 12: 1756286419845567
• 15 Butterfield RJ. Congenital muscular dystrophy and congenital myopathy. Continuum (Minneap Minn) 2019; 25 (06) 1640-1661
• 16 Klein A, Clement E, Mercuri E, Muntoni F. Differential diagnosis of congenital muscular dystrophies. Eur J Paediatr Neurol 2008; 12 (05) 371-377
• 17 Mah JK, Korngut L, Fiest KM. et al. A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci 2016; 43 (01) 163-177
• 18 Peat RA, Smith JM, Compton AG. et al. Diagnosis and etiology of congenital muscular dystrophy. Neurology 2008; 71 (05) 312-321
• 19 Lim BC, Lee S, Shin JY. et al. Molecular diagnosis of congenital muscular dystrophies with defective glycosylation of alpha-dystroglycan using next-generation sequencing technology. Neuromuscul Disord 2013; 23 (04) 337-344
• 20 Benarroch L, Bonne G, Rivier F, Hamroun D. The 2020 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord 2019; 29 (12) 980-1018
• 21 Dowling JJ, Gonorazky HD, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: The future is now. Am J Med Genet A 2018; 176 (04) 804-841
• 22 Calvert LD, McKeever TM, Kinnear WJ, Britton JR. Trends in survival from muscular dystrophy in England and Wales and impact on respiratory services. Respir Med 2006; 100 (06) 1058-1063